Medical Crossfire®: Hot Topics in Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors (PCSK9i)

Released On
June 29, 2018

Expires On
June 29, 2019

Media Type
Internet

Completion Time
90 minutes

Specialty
Lipidology, Cardiology

Topic(s)
PCSK9 Inhibitors

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians' Education Resource®, LLC.


Supported by an educational grant from Amgen.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.5 contact hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This CME activity is primarily intended for lipidologists and cardiologists. Nurses, physician assistants, and other health care professionals interested in the treatment of hypercholesterolemia are also invited to participate.

Program Overview

During this Medical Crossfire®, a panel of leading cardiologists and lipid specialists will review the latest indications for PCSK9 inhibitors along with the updated ACC Expert Consensus and National Lipid Association Expert Panel Recommendations incorporating nonstatin therapies into clinical practice. Recent clinical trial data for evolocumab and alirocumab will be reviewed. A brief summary of the FOURIER trial will lead into analysis of new data that identifies high-risk subgroups that demonstrated treatment benefits. ODYSSEY OUTCOMES will be reviewed and the clinical implications of that data will be put it into context with FOURIER results. The final segment will focus on barriers that have prevented the uptake of PCSK9 inhibitors into clinical practice. The panelists will share practical and effective strategies for increasing prior authorization approval rates as well as the need for education on the benefits of nonstatin therapy for both prescribing clinicians and patients.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • DESCRIBE the latest clinical guidelines and recommendations for the use of proprotein convertase subtilisin kexin type 9 inhibitors (PCKS9i)
  • ELUCIDATE recent findings from cardiovascular outcomes studies of PCSK9i
  • APPLY the results of PCSK9i cardiovascular outcomes trials to manage patients with high risk of an atherosclerotic cardiovascular event
  • IMPLEMENT processes that would be expected to improve payer approval of PCSK9i prescriptions

Faculty

Marc S. Sabatine, MD, MPH

Chairman, TIMI Study Group
Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel Soffer, MD, FNLA, FACP

Clinical Associate Professor of Medicine
Perelman School of Medicine
The University of Pennsylvania
Philadelphia, Pennsylvania

James Underberg, MD

Immediate Past President of the National Lipid Association
Clinical Assistant Professor of Medicine
New York University School of Medicine
New York, New York

Karol Watson, MD, PhD

Professor of Medicine, Cardiology/Cardiovascular Disease
David Geffen School of Medicine at UCLA
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
Los Angeles, California

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and is a provider approved by the California Board of Registered Nursing (CBRN).

Credit Designation Statement

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ and for 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other health care professionals completing this course will be issued a statement of participation.

Disclosures of Conflicts of Interest

Marc S. Sabatine, MD, MPH

  • Grant/Research Support: Brigham and Women’s Hospital from Amgen, AstraZeneca, Daiichi Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen Research and Development, Medicines Company, MedImmune, Merck, Novartis, Pfizer, Poxel, Takeda
  • Consultant: Amgen, AstraZeneca, Bristol-Myers Squibb, CVS Caremark, Dyrnamix, Esperion, Intarcia, Janssen Research and Development, Medicines Company, MedImmune, Merck, Novartis

Daniel Soffer, MD, FNLA, FACP

  • Grant/Research Support: Akcea/Ionis, Amgen, AstraZeneca, Kowa, Novartis, Sanofi, Regeneron, Regenix/NIH
  • Consultant: Akcea, Amgen
  • Speaker’s Bureau: Akcea, NLA

James Underberg, MD

  • Grant/Research Support: Aegerion, Pfizer
  • Consultant: Amarin, Amgen
  • Speaker’s Bureau: Alexion, Amarin, Amgen, Kowa, Regeneron, Sanofi, True Health Diagnostics

Karol Watson, MD, PhD

  • Consultant: Amgen, Boehringer Ingelheim/Lily, Kowa

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.